Table 1 Demographic and clinical characteristics of the patients of each cohort at baseline

From: Homotypic and heterotypic immune responses to Omicron variant in immunocompromised patients in diverse clinical settings

Characteristics

Cohort 1

(N = 91)

Cohort 2

(N = 75)

Cohort 3

(N = 60)

Cohort 4

(N = 20)

Age—years (mean ± SD)

54.2 ± 14.1

53.5 ± 12.7

67.7 ± 4.8

45.4 ± 10.7

Female sex—no. (%)

23 (25%)

26 (35%)

23 (38%)

15 (75%)

Type of transplant—no. (%)

Kidney

48 (52.7%)

30 (40%)

20 (33.3%)

 

Lung

16 (17.6%)

16 (21.3%)

11 (18.3%)

 

Liver

19 (20.9%)

11 (14.7%)

3 (5%)

 

Heart

3 (3.3%)

6 (8%)

10 (16.7%)

 

Kidney–pancreas

4 (4.4%)

9 (12%)

15 (25%)

 

Kidney–liver

1 (1.1%)

3 (4%)

1 (1.67%)

 

Years since transplant (median, IQR)a

5.4 (2.3–9.1)

5.9 (2.3–9.9)

3.8 (2.0–6.7)

 

Immunosuppressant—no. (%)

Prednisone

73 (80.2%)

64 (85.3%)

50 (83.3%)

 

Tacrolimus

81 (89%)

63 (84%)

47 (78.3%)

 

Cyclosporine

3 (3.3%)

10 (13.3%)

12 (20%)

 

Mycophenolate

65 (71.4%)

62 (82.7%)

44 (73.3%)

 

Azathioprine

9 (9.9%)

2 (2.6%)

7 (11.7%)

 

Sirolimus

1 (1.1%)

1 (1.3%)

2 (3.3%)

 

Antilymphocyte globulin last 3 months

4 (4.4%)

1 (1.3%)

0 (0%)

 

No. of COVID-19 vaccines—no. (%)

0

72 (79.1%)

3 (4%)

0 (0%)

0 (0%)

1

5 (5.5%)

2 (2.7%)

0 (0%)

0 (0%)

2

14 (15.4%)

12 (16%)

0 (0%)

0 (0%)

3

0 (0%)

53 (70.7%)

60 (100%)

20 (100%)

4

0 (0%)

5 (6.7%)

0 (0%)

0 (0%)

Vaccine brand—no. (%)

BNT162b2 (Pfizer–BioNTech)

10 (52.6%)

35 (48.6%)

0 (0%)

20 (100%)

mRNA-1273 (Moderna)

7 (36.8%)

7 (9.7%)

60 (100%)

0 (0%)

ChAdOx1-S (AstraZeneca)

2 (10.5%)

0 (0%)

0 (0%)

0 (0%)

Mix

0 (0%)

4 (5.6%)

0 (0%)

0 (0%)

Unknown brand but mRNA vaccine

0 (0%)

26 (36.11%)

0 (0%)

0 (0%)

SARS-CoV-2-related hospitalization

46 (51%)

11 (15%)

  

SARS-CoV-2 severe diseaseb

29 (32%)

6 (8%)

  
  1. Cohort 1 includes transplant recipients with COVID-19 diagnosis before the Omicron wave. Cohort 2 includes transplant recipients recovered from Omicron-BA.1 infection. Cohort 3 includes uninfected transplant recipients with 3 doses of mRNA-1273 (Moderna) vaccine. Cohort 4 includes uninfected healthcare workers with 3 doses of BNT162b2 (Pfizer–BioNTech) vaccine.
  2. IQR Interquartile range, SD Standard deviation.
  3. aYears from transplant to infection in case of cohort 1 and 2, and from transplant to last dose of the vaccine in case of cohort 3.
  4. bSARS-CoV-2 severe disease includes any patient that required supplementary oxygen.
Back to article page